Drinidene is the analgesic agent.

Metogest, a hormone, is a progesterone receptor agonist. Metogest was used in acne treatment. However, this drug has never been marketed.

Idaverine, a muscarinic M2 receptor antagonist, that didn’t prevent motion sickness of cats. Clinical trials for human have shown that the compound was well tolerated.

Dimethadione (5,5-dimethyl-2,4-oxazolidinedione) is the N-demethylated metabolite of the anticonvulsant trimethadione. Dimethadione is considered to be a blocker of T-type calcium channel. Dimethadione also inhibits a specific potassium channel (Ikr) in HERG-transfected cells. It exerts teratogenic effect especially congenital heart defects. Dimethadione can be used for the measurement of regional tissue pH using positron emission tomography.

Etoxadrol is an NMDA receptor antagonist. It exerts phencyclidine-like properties. Etoxadrol has anticonvulsant and anesthetic activity. Intravenous etoxadrol was clinically tested as an anesthetic.

Bucrylate (isobutyl cyanoacrylate) is a liquid tissue adhesive for transcatheter embolization. It is used in radiological and endoscopic interventions to occlude vessels and to stop bleedings. In comparison with sponges, coils and plugs, bucrylate is inexpensive and achieves immediate, irreversible and complete occlusion of the vessel irrespective of coagulation deficiencies.

Quingestrone is a progestin, or a synthetic progestogen, patented by Laboratoires francais de chimiotherapie as an anti-inflammatory agent. Quingestrone acts as an agonist of the progesterone receptor weak glucocorticoid activity. Quingestrone was formerly used in combination with ethinylestradiol or mestranol in combined birth control pills in Italy. The medication was studied in the clinical prevention of miscarriage during pregnancy, but insufficient efficacy was observed at the dosage assessed

Nifurmerone, a 5-nitrofuran derivative, is an antifungal agent.

CE-224535 is a potent, highly selective, orally bioavailable, non-competitive antagonist of the human P2X7 receptor. Pre-clinical pharmacokinetic studies with CE-224535 indicate limited CNS penetration. In clinical trials, CE-224535 failed to demonstrate efficacy in a 2-week study of knee pain in osteoarthritis or a 12-week study in patients with rheumatoid arthritis. CE-224535 is safe and well tolerated after administration of up to 1600 mg as a single dose or 600 mg every 12 hours for 14 days in healthy subjects and 500 mg every 12 hours for 2 weeks in subjects with osteoarthritis of the knee and 12 weeks in rheumatoid arthritis patients with an inadequate response to methotrexate.

Amotriphene (Myordil, WIN 5494) is a coronary dilator and cardiac antiarrhythmic properties. It has potential value in the treatment of angina-like conditions and the milder cardiac arrhythmias. Amotriphene binds to α‐adrenergic receptors.